JUN 11, 2016 12:22 PM PDT

New Approach to Vaccines: Activate Only When Needed

WRITTEN BY: Carmen Leitch
A new vaccine has been developed that allows bacteria to grow inside the body, only actively fighting microbes that cause disease. This approach works in a completely nontraditional way; vaccines usually work to destroy bacteria before it has a chance to grow at all.
 Scanning electron micrograph of Streptococcus pneumoniae
Blaine Pfeifer, an Associate Professor of chemical and biological engineering at the University at Buffalo School of Engineering and Applied Sciences, and colleagues conducted the work, which was published in the Proceedings of the National Academy of Sciences and describes a vaccine responding to pneumococcus. 

"With conventional vaccines, the approach has been: 'What bacteria do we want to target and how,'" says Charles Jones, a study author who founded Abcombi Biosciences, a company spearheading the effort to bring this vaccine to market. "Our strategy is to shift the paradigm to which diseases do we want to prevent."

Pneumococcus is the common name for Streptococcus pneumoniae, and pneumococcal infections can result in many types of illnesses such as ear infections, pneumonia and meningitis. "These are very serious illnesses that we haven't been able to completely suppress. The vaccine we're developing could finally get that job done," says Pfeifer.

 According to the CDC, roughly 900,000 Americans contract pneumococcal pneumonia each year, causing an estimated 400,000 hospitalizations. It is fatal for 5-7 percent - about 3,700 patients. Outside the United States, especially in underdeveloped nations, the number of deaths is much higher.

Doctors have long relied on medications like penicillin to treat sickness caused by pneumococcus, and their effectiveness has been in decline for a long time. That problem led to the creation of vaccines, which have helped to reduce illness and death. But, vaccines that are commonly used only target a small number of strains of the virulent bacteria - the ones that cause the most serious illnesses. They find the bacteria by identifying a sugar coating that surrounds it.

This new vaccine instead uses proteins on the surface of the bacteria as the identifying feature. Tests that evaluated the new vaccine showed that it defended against 12 strains of the bacteria with 100 percent effectiveness. Computer models suggest it could be used against many more strains but further testing is needed to confirm.

With multiple diseases caused by a variety of strains, this approach could be a great way to respond to myriad illnesses. 
 (A) S. pneumoniae grows in the nasal passages, producing a bacterial biofilm that provides protection. External triggers like viral infection prompt the active release of virulent pneumococci that disseminate and cause disease. (B) Leading vaccination strategies [polysaccharide conjugate vaccines] mediate protection against some bacterial serotypes by clearing pneumococci before biofilm establishment. But clearing all bacteria opens vulnerabilities to colonization by nonvaccine serotypes or other bacterial species. (C) The strategy featured in this work mediates clearance of only virulent biofilm-released bacteria while keeping the presence of the preexisting biofilm. Source: PNAS
The novel strategy of this vaccine is to let bacteria live, so long as it does not cause any harm to the body. It teaches the immune system to only attack when the proteins on the surface of the bacterial coating break free. “That’s the signal that this bacteria is becoming a troublemaker, that’s its threatening the body and that it’s necessary to fight back,” Pfeifer says.

The vaccine has so far been tested and found to be effective in animals; Abcombi currently leads efforts to conduct trials in humans.

Sources: CDC, University at Buffalo News Center via AAAS, PNAS
About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
AUG 25, 2020
Drug Discovery & Development
The Potential of Antivitamins
AUG 25, 2020
The Potential of Antivitamins
What exactly are antivitamins? They are substances no less that have the power to target the biological function of a ge ...
SEP 11, 2020
Microbiology
Bat Ticks Are Discovered in New Jersey
SEP 11, 2020
Bat Ticks Are Discovered in New Jersey
While only about 25 of 900 species of tick spread disease, ticks are responsible for an estimated 95 percent of vector-b ...
NOV 05, 2020
Clinical & Molecular DX
Digging DEEP into Metabolomic Space
NOV 05, 2020
Digging DEEP into Metabolomic Space
Metabolomics is an umbrella term encompassing lipidomics and the study of smaller polar metabolites.  As such, more ...
NOV 19, 2020
Immunology
Parasitic Worms Help Unravel the Immune Mechanisms Underlying Chronic Disease
NOV 19, 2020
Parasitic Worms Help Unravel the Immune Mechanisms Underlying Chronic Disease
Parasitic worms known as helminths have a complicated relationship with the immune systems of the hosts they invade. Ter ...
NOV 20, 2020
Microbiology
Heavy Metal Exposure Raises Levels of Antibiotic-Resistant Germs in Cows
NOV 20, 2020
Heavy Metal Exposure Raises Levels of Antibiotic-Resistant Germs in Cows
Antibiotic-resistant microbes are considered to be a major public health threat. The overuse of antibiotics is thought t ...
NOV 28, 2020
Microbiology
Potential Treatment ID'ed for Emerging Viral Disease
NOV 28, 2020
Potential Treatment ID'ed for Emerging Viral Disease
A mosquito-borne virus called VEEV has been emerging in South America. It causes symptoms that make it difficult to dist ...
Loading Comments...